Please assess the completion status of the following clinical trial:

Trial Title: Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria :~* Subjects who the investigator/co-investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.~* A Japanese female subject between, and including, 20 and 25 years of age at the time of the first vaccination.~* Written informed consent obtained from the subject prior to enrolment.~* Healthy subjects as established by medical history and history-oriented clinical examination before entering into the study.~* Subjects must have a negative urine pregnancy test.~* Subjects must be of non-childbearing potential, she must be abstinent or have used adequate contraceptive precautions for 30 days prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for two months after completion of the vaccination series.~* Subject must have an intact cervix~Exclusion criteria:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine/control within 30 days preceding the first dose of study vaccine/control, or planned use during the study period.~* Pregnant or breastfeeding women. Women must be at least 3 months post-pregnancy and not breastfeeding to enter the study.~* A women planning to become pregnant, likely to become pregnant or planning to discontinue contraceptive precautions during the study period, up to 2 months after the last vaccine dose~* previous administration of components of the investigational vaccine~* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.~* Planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days before and 30 days after the first dose of vaccine. Routine vaccines may be allowed up to 8 days before the first dose of study vaccine.~* Previous vaccination against HPV.~* History of vaccination against hepatitis A or a known clinical history of hepatitis A disease~* Administration of immunoglobulin and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.~* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination~* History of allergic disease or reactions likely to be exacerbated by any component of the study vaccines~* Hypersensitivity to latex~* Known acute or chronic, clinically significant pulmonary, cardiovascular, neurologic, hepatic or renal functional abnormality, as determined by previous physical examination or laboratory tests.~* Cancer or autoimmune disease under treatment.~* History of having had colposcopy or has planned a colposcopy to evaluate an abnormal cervical cytology (Pap smear) test.~* Heavy bleeding or heavy vaginal discharge such that a pelvic examination can not be performed~* Acute disease at the time of enrolment.~* Oral temperature \>= 37.5°C / axillary temperature \> 37.5°C.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Study Arms:
- Cervarix Group (Type: EXPERIMENTAL): Subjects received 3 doses of GSK Biologicals HPV-16/18 vaccine (Cervarix™) according to a 0, 1, 6-month schedule.
- Aimmugen Group (Type: ACTIVE_COMPARATOR): Subjects received 3 doses of Aimmugen™ (Hepatitis A \[HAV\] vaccine) according to a 0, 1, 6-month schedule.

Based on this trial design, predict the completion outcome and termination type (if applicable).